A Phase 1 interventional study of Nomlabofusp and Placebo in Friedreich Ataxia, sponsored by Larimar Therapeutics, Inc.. Terminated at 1 site in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Larimar Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.
Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 37th largest by enrollment of the 49 interventional ones that give a count, is one of 7 that started in 2024, is one of 15 in phase 1, and was the 60th registered.
111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.
Browse Friedreich Ataxia studies →18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:
Biogen · Sites in United States
Ages 16+ · Women only
Larimar Therapeutics, Inc. · Sites in United States
Ages 12–40
Scott Barbuto · Sites in United States
Lexeo Therapeutics · Sites in United States
Ages 6+
Solid Biosciences Inc. · Sites in United States
Ages 18–40
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 19 · Phase 3 12
First in 2001; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 30 across 76 interventional studies indexed under Friedreich Ataxia.
Median enrollment 32 across the 49 interventional studies, 65 across the 21 observational. Of the 43 that completed or were terminated, 16 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 71 have an industry lead sponsor. The 10 most frequent:
Larimar Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Larimar Therapeutics, Inc. has 8 studies filed under Friedreich Ataxia — fewer than ten, so there is no comparison to draw.
6 of the studies in Friedreich Ataxia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953583Phase 3BiogenA Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia | 2027-11-16 |
| NCT06447025Larimar Therapeutics, Inc.An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia | 2027-01 |
| NCT07869654Adjuvia Therapeutics, Inc.A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults | 2027-05-27 |
| NCT07870590Graviton Bioscience CorporationGV101 for Friedreich's Ataxia (FA) Treatment | 2027-07 |
| NCT02316314Weill Medical College of Cornell UniversityCharacterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA) | 2027-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 71 studies in Friedreich Ataxia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the safety and tolerability of nomlabofusp (CTI-1601) in adolescents and children with Friedreich's ataxia (FRDA).
This is a randomized, double-blind, placebo-controlled study evaluating a weight-based dose of nomlabofusp versus placebo in adolescents and children with FRDA. The study will consist of at least two cohorts with at least 12 to 15 participants in each cohort. Participants will be dosed once daily (QD) for 7 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must be able to traverse a distance of 25 feet with or without some assistive device (e.g., cane, walker, crutches, self-propelled wheelchair) and meet the following requirements:
Exclusion Criteria:
Subcutaneous injection of 0.8 mg/kg, with a maximum dose of 50 mg, once daily for 7 days
Drug: Nomlabofusp
Subcutaneous injection once daily for 7 days
Drug: Placebo
Nomlabofusp is a recombinant fusion protein provided in a sterile, preservative-free buffered solution for subcutaneous injection intended to deliver human frataxin, the protein deficient in Friedreich's ataxia.
Also known as: CTI-1601
The placebo is a sterile, preservative-free, clear liquid for subcutaneous injection.
Also known as: CTI-1601 Placebo, Nomlabofusp Placebo
Number of AEs, TEAEs, related TEAEs, Grade 3/4 TEAEs, and SAEs
Number
Time frame: Up to 72 days (including screening)
Number of subjects with ISRs
Number
Time frame: Up to 37 days
Change from baseline in electrocardiogram (ECG) parameter - heart rate (HR)
Number
Time frame: Baseline, Day 7
Change from baseline in electrocardiogram (ECG) parameter - PR interval
Number
Time frame: Baseline, Day 7
Change from baseline in electrocardiogram (ECG) parameter - QRS complex
Number
Time frame: Baseline, Day 7
Change from baseline in electrocardiogram (ECG) parameter - QT interval
Number
Time frame: Baseline, Day 7
Change from baseline in electrocardiogram (ECG) parameter - QTcF (Corrected QT Interval)
Number
Time frame: Baseline, Day 7
Change from baseline in echocardiogram (ECHO) parameter - ejection fraction (EF)
Number
Time frame: Baseline, Day 7
Change from baseline in echocardiogram (ECHO) parameter - left ventricular end-diastolic volume (LV EDV)
Number
Time frame: Baseline, Day 7
Change from baseline in echocardiogram (ECHO) parameter - left ventricular end-systolic volume (LV ESV)
Number
Time frame: Baseline, Day 7
Change from baseline in echocardiogram (ECHO) parameter - relative wall thickness (RWT)
Number
Time frame: Baseline, Day 7
Change from baseline in echocardiogram (ECHO) parameter - left ventricular mass (LVM)
Number
Time frame: Baseline, Day 7
Change from baseline in echocardiogram (ECHO) parameter - left ventricular posterior wall thickness
Number
Time frame: Baseline, Day 7
Change from baseline in echocardiogram (ECHO) parameter - septal wall thickness
Number
Time frame: Baseline, Day 7
Change from baseline in echocardiogram (ECHO) parameter - mitral valve inflow Doppler
Number
Time frame: Baseline, Day 7
Change from baseline in echocardiogram (ECHO) parameter - tissue Doppler
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - sodium
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - potassium
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - glucose
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - blood urea nitrogen
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - creatinine
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - calcium, chloride
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - phosphorus
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - total protein
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - total CO2
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - albumin
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - AST
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - ALT
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - GGT
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - ALP
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - total bilirubin
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - uric acid
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - HbA1c
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - hemoglobin
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - hematocrit
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - RBC count
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - RDW
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - MCV
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - MCH
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - platelet count
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - WBC count
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - ANC
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - Eosinophils
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - Monocytes
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - Basophils
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - Lymphocytes
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - Bands
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - Neutrophils
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - Cholesterol
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - HDL cholesterol
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - LDL cholesterol
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - Triglycerides
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - very low-density lipoprotein cholesterol
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - pH
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - protein
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - blood
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - ketones
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - bilirubin
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - urobilinogen
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - nitrites
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - leukocyte esterase
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - color
Number
Time frame: Baseline, Day 7
Change from baseline in clinical laboratory assessment - specific gravity
Number
Time frame: Baseline, Day 7
Change from baseline in pulse rate
Number
Time frame: Baseline, Day 7
Number of subjects with abnormal physical examinations
Number
Time frame: Up to 72 days (including screening)
Number of subjects with suicidal ideation, suicidal behavior, and suicidal ideation or behavior based on the Columbia Suicide Severity Rating Scale (C-SSRS)
Number
Time frame: Up to 72 days (including screening)
Number of subjects who discontinue treatment and/or study
Number
Time frame: Up to 37 days
AUC0-last
Area under the concentration-time-curve to the last quantifiable timepoint
Time frame: Days 1, 7
Cmax
Maximum observed concentration
Time frame: Days 1, 7
Tmax
Time of maximum observed concentration
Time frame: Days 1, 7
Ctrough
Predose concentration
Time frame: Days 1, 7
Change from baseline in FXN concentrations normalized to total protein observed in buccal cells collected from cheek swabs
Number
Time frame: Baseline, Day 7
Plan to share: No
Ran from Dec 2024 to primary completion in Apr 2025, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nomlabofusp
Larimar Therapeutics, Inc.